Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of “Moderate Buy” from Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has earned an average recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $137.3333.

MIRM has been the topic of a number of recent analyst reports. Evercore reiterated an “outperform” rating and set a $138.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a research note on Monday, June 15th. HC Wainwright reduced their target price on Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a report on Thursday. Finally, Robert W. Baird set a $123.00 price target on Mirum Pharmaceuticals in a research note on Thursday.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total transaction of $326,520.00. Following the transaction, the senior vice president owned 3,114 shares in the company, valued at $373,680. This represents a 46.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 67,155 shares of company stock valued at $7,185,662. 8.32% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIRM. Contravisory Investment Management Inc. raised its position in shares of Mirum Pharmaceuticals by 2.3% during the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock valued at $539,000 after buying an additional 103 shares during the last quarter. Faithward Advisors LLC grew its stake in Mirum Pharmaceuticals by 0.5% during the first quarter. Faithward Advisors LLC now owns 27,467 shares of the company’s stock valued at $2,537,000 after acquiring an additional 126 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock valued at $253,000 after acquiring an additional 200 shares in the last quarter. Comerica Bank increased its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the last quarter. Finally, Osaic Holdings Inc. increased its holdings in Mirum Pharmaceuticals by 46.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after acquiring an additional 351 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

MIRM opened at $94.11 on Friday. The stock has a 50-day moving average price of $110.35 and a 200-day moving average price of $101.79. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The firm has a market cap of $5.74 billion, a PE ratio of -6.47 and a beta of 0.52. Mirum Pharmaceuticals has a 1 year low of $54.74 and a 1 year high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The firm had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 26.88%. The business’s revenue for the quarter was up 37.9% compared to the same quarter last year. During the same period last year, the company posted ($0.12) earnings per share. Sell-side analysts predict that Mirum Pharmaceuticals will post -2.01 earnings per share for the current fiscal year.

Mirum Pharmaceuticals News Roundup

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of approximately $176.2 million, ahead of the $166.3 million analyst consensus and up 37.9% year over year. Growth from Livmarli and other bile-acid medicines supported the performance. Mirum Q2 earnings and 2026 outlook
• Positive Sentiment: The company raised its 2026 revenue guidance to $680 million-$700 million, above the roughly $675.1 million consensus estimate, reinforcing expectations for continued product-driven growth.
• Positive Sentiment: Despite reducing their targets, TD Cowen and HC Wainwright maintained “buy” ratings at $140, while Citizens JMP kept a “market outperform” rating with a $137 target. These targets imply substantial potential upside from recent trading levels. Analyst price target updates
• Neutral Sentiment: Analysts continue to view Mirum favorably overall, but the target reductions—from as high as $185 previously—indicate that near-term risks and valuation assumptions have become more cautious.
• Negative Sentiment: Citizens warned that the FDA made an “unexpected” request for an additional Phase 3 study, clouding Mirum’s near-term outlook. The request raises potential development costs and could delay regulatory progress, which was the primary catalyst behind the selloff. Citizens FDA assessment
• Negative Sentiment: Second-quarter earnings missed expectations: Mirum reported a larger-than-expected per-share loss, while the loss widened from the prior-year period. The company remains unprofitable, increasing investor sensitivity to clinical spending and regulatory delays. Mirum quarterly earnings report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734 under a pre-arranged Rule 10b5-1 plan. The scheduled nature limits its significance, but the transaction reduced her direct holdings by about 59%. Mirum insider sale

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.